9783848424382 - Nasal Drug Delivery: Development and Evaluation of Nasal Formulation di Nanjwade, Basavaraj; A. Parikh, Kemy (8 risultati)

Taschenbuch. Condizione: Neu. Gebraucht - Sehr gut verlagsfrische Restauflage, minimale Lagerspuren, ungelesen, sehr guter Zustand -Microsphere carrier systems made from the biodegradable polymers have attracted considerable attention for several years in sustained drug delivery. However, the short residence time at the site of absorption could be overcome by coupling bioadhesion characteristics to microspheres and developing bioadhesive microspheres with the help of bioadhesive polymers. Neostigmine Bromide a cholinesterase inhibitor is widely used for the treatment of Myasthenia Gravis. It is presently marketed in conventional dosage form as a tablet in usual strength of 15-30 mg for peroral route. Extent of absorption of drug through oral route is only 1-2% of 30 mg of administered dose. Hence there is need of novel nasal drug delivery system for the treatment of Myasthenia Gravis. To overcome inherent drawbacks associated with conventional dosage forms of Neostigmine Bromide, an attempt is being made in the present research work to develop an alternative drug delivery system in the form of Nasal mucoadhesive microspheres to increase the rate and extent of absorption and to reduce the dosing frequency of the formulation. 168 pp. Englisch.

Taschenbuch. Condizione: Neu. Gebraucht - Sehr gut verlagsfrische Restauflage, minimale Lagerspuren, ungelesen, sehr guter Zustand -Microsphere carrier systems made from the biodegradable polymers have attracted considerable attention for several years in sustained drug delivery. However, the short residence time at the site of absorption could be overcome by coupling bioadhesion characteristics to microspheres and developing bioadhesive microspheres with the help of bioadhesive polymers. Neostigmine Bromide a cholinesterase inhibitor is widely used for the treatment of Myasthenia Gravis. It is presently marketed in conventional dosage form as a tablet in usual strength of 15-30 mg for peroral route. Extent of absorption of drug through oral route is only 1-2% of 30 mg of administered dose. Hence there is need of novel nasal drug delivery system for the treatment of Myasthenia Gravis. To overcome inherent drawbacks associated with conventional dosage forms of Neostigmine Bromide, an attempt is being made in the present research work to develop an alternative drug delivery system in the form of Nasal mucoadhesive microspheres to increase the rate and extent of absorption and to reduce the dosing frequency of the formulation. 168 pp. Englisch.

Condizione: New.

Taschenbuch. Condizione: Neu. Nasal Drug Delivery | Development and Evaluation of Nasal Formulation | Basavaraj Nanjwade (u. a.) | Taschenbuch | 168 S. | Englisch | 2012 | LAP LAMBERT Academic Publishing | EAN 9783848424382 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu.

Paperback. Condizione: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Microsphere carrier systems made from the biodegradable polymers have attracted considerable attention for several years in sustained drug delivery. However, the short residence time at the site of absorption could be overcome by coupling bioadhesion characteristics to microspheres and developing bioadhesive microspheres with the help of bioadhesive polymers. Neostigmine Bromide a cholinesterase inhibitor is widely used for the treatment of Myasthenia Gravis. It is presently marketed in conventional dosage form as a tablet in usual strength of 15-30 mg for peroral route. Extent of absorption of drug through oral route is only 1-2% of 30 mg of administered dose. Hence there is need of novel nasal drug delivery system for the treatment of Myasthenia Gravis. To overcome inherent drawbacks associated with conventional dosage forms of Neostigmine Bromide, an attempt is being made in the present research work to develop an alternative drug delivery system in the form of Nasal mucoadhesive microspheres to increase the rate and extent of absorption and to reduce the dosing frequency of the formulation. 168 pp. Englisch.

Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Microsphere carrier systems made from the biodegradable polymers have attracted considerable attention for several years in sustained drug delivery. However, the short residence time at the site of absorption could be overcome by coupling bioadhesion characteristics to microspheres and developing bioadhesive microspheres with the help of bioadhesive polymers. Neostigmine Bromide - a cholinesterase inhibitor is widely used for the treatment of Myasthenia Gravis. It is presently marketed in conventional dosage form as a tablet in usual strength of 15-30 mg for peroral route. Extent of absorption of drug through oral route is only 1-2% of 30 mg of administered dose. Hence there is need of novel nasal drug delivery system for the treatment of Myasthenia Gravis. To overcome inherent drawbacks associated with conventional dosage forms of Neostigmine Bromide, an attempt is being made in the present research work to develop an alternative drug delivery system in the form of Nasal mucoadhesive microspheres to increase the rate and extent of absorption and to reduce the dosing frequency of the formulation.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 168 pp. Englisch.

Taschenbuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Microsphere carrier systems made from the biodegradable polymers have attracted considerable attention for several years in sustained drug delivery. However, the short residence time at the site of absorption could be overcome by coupling bioadhesion characteristics to microspheres and developing bioadhesive microspheres with the help of bioadhesive polymers. Neostigmine Bromide a cholinesterase inhibitor is widely used for the treatment of Myasthenia Gravis. It is presently marketed in conventional dosage form as a tablet in usual strength of 15-30 mg for peroral route. Extent of absorption of drug through oral route is only 1-2% of 30 mg of administered dose. Hence there is need of novel nasal drug delivery system for the treatment of Myasthenia Gravis. To overcome inherent drawbacks associated with conventional dosage forms of Neostigmine Bromide, an attempt is being made in the present research work to develop an alternative drug delivery system in the form of Nasal mucoadhesive microspheres to increase the rate and extent of absorption and to reduce the dosing frequency of the formulation.